Brayton Purcell LLP

Call For A Free Consultation
800-598-0314

Call For A Free Consultation 800-598-0314

Brayton Purcell LLP
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Contact
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Contact

New drug trials in the fight against mesothelioma

On behalf of Brayton Purcell LLP | Sep 24, 2013 | Mesothelioma

Mesothelioma is like an inevitable bookend to asbestos exposure. What begins as a few microscopic fibers of the mineral asbestos, so slight they float through the air, ends as a cancerous, hardened lining of the lung, making breathing difficult and eventually leading to death.

Asbestos, a seemingly innocuous mineral that was so useful, providing insulation from heat in everything from fire-proof firefighting suits to pipe insulation around the world, to hot pan holders in your grandma’s kitchen in California, poses a great and deadly danger to those who are exposed to the aerosolized fibers.

In the United Kingdom, mesothelioma deaths have climbed from less than two hundred a year in the sixties to more than two thousand today. Research is ongoing to develop a treatment that would improve the survival chances and the quality of life of those who contract mesothelioma after inhaling asbestos’s deadly fibers.

One study in the United Kingdom involves a drug known as ganetespib that is designed to prevent mesothelioma tumors. The drug interferes with the functioning of a protein that is necessary for the tumor to grow.

A second study looks at the drug defactinib, which acts on the focal adhesion kinase (FAK), which is used by the cancer stem cells as they develop into cancerous tumors. This study will involve patients from around the world.

The doctor from the University of Leicester is hopeful that by inhibiting the FAK in the mesothelioma stem cells, the use of chemotherapy will be more effective, as stem cells can trigger regrowth of cancer tumors. If the stem cell growth is stopped by defactinib, it could improve the chances of stopping any new tumor growth.

Source: Science Daily, “Mesothelioma: Two Groundbreaking Trials Into Treatments for Asbestos-Related Cancer,” September 23, 2013

Recent Posts

  • EPA Risk Evaluation for Chrysotile Asbestos
  • Caring for Someone with Mesothelioma: What to Know
  • 2020 shows promise in the fight for a mesothelioma cure
  • Asbestos in Makeup Products Is a Problem That Is Not Going Away
  • How Did I Get Mesothelioma?

Archives

Categories

RSS Feed

Subscribe To This Blog’s Feed

Free Consultation

Take The First Step In Resolving Your Issue. Send Us An Email.

Email Us For A Response

San Francisco
Bay Area Office

222 Rush Landing Road Novato, CA 94945

Novato Office
222 Rush Landing Road
Novato, CA 94945
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions

Southern California
Office

12 28th Street Venice, California 90291

Los Angeles Office
12 28th Street
Venice, California 90291
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2021 Brayton Purcell LLP. All Rights Reserved.

Disclaimer | Site Map | Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters

Review Us